SLC5A2 and diabetes mellitus: Over the last 10 years, landmark cardiovascular trials have demonstrated significant benefits with certain groups of glucose-lowering medications, including sodium-glucose co-transport-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RA), transforming recommendations and treatment options for those with DM (10, 11).